Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus

Andreas B Petersen,1 Mikkel Christensen1,21Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark; 2Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, Copenhagen, DenmarkAbstract: The glucagon-like peptide (GLP)-1 receptor agonist lixisenatide (Lyx...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Petersen AB, Christensen M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/7b095839cdb5437283aae518cecf7f0c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7b095839cdb5437283aae518cecf7f0c
record_format	dspace
spelling	oai:doaj.org-article:7b095839cdb5437283aae518cecf7f0c2021-12-02T01:44:25ZClinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus1178-7007https://doaj.org/article/7b095839cdb5437283aae518cecf7f0c2013-06-01T00:00:00Zhttp://www.dovepress.com/clinical-potential-of-lixisenatide-once-daily-treatment-for-type-2-dia-a13353https://doaj.org/toc/1178-7007Andreas B Petersen,1 Mikkel Christensen1,21Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark; 2Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, Copenhagen, DenmarkAbstract: The glucagon-like peptide (GLP)-1 receptor agonist lixisenatide (Lyxumia®) was approved for marketing by the European Medicines Agency in February 2013 and has been evaluated in a clinical study program called GetGoal. Lixisenatide activates the GLP-1 receptor and thereby exercises the range of physiological effects generated by GLP-1, which consist of increased insulin secretion, inhibition of glucagon secretion, and decreased gastrointestinal motility alongside the promotion of satiety. In the GetGoal study program, lixisenatide demonstrated significant reductions in glycated hemoglobin (HbA1c), and fasting and postprandial plasma glucose compared with placebo. The effect on glycemia was evident, with both monotherapy and in combination with insulin and various oral antidiabetic agents. Furthermore, a general trend towards reduced bodyweight was reported. In head-to-head trials with the other GLP-1 receptor agonists (exenatide and liraglutide) on the market, lixisenatide demonstrated a superior effect with respect to reduction in postprandial plasma glucose and had a tendency towards fewer adverse events. However, lixisenatide seemed to be less efficient or at best, equivalent to exenatide and liraglutide in reducing HbA1c, fasting plasma glucose, and bodyweight. The combination of a substantial effect on postprandial plasma glucose and a labeling with once daily administration separates lixisenatide from the other GLP-1 receptor agonists. The combination of basal insulin, having a lowering effect on fasting plasma glucose, and lixisenatide, curtailing the postprandial glucose excursions, makes sense from a clinical point of view. Not surprisingly, lixisenatide is undergoing clinical development as a combination product with insulin glargine (Lantus®). At present the main place in therapy of lixisenatide seems to be in combination with basal insulin. A large multicenter study will determine the future potential of lixisenatide in preventing cardiovascular events and mortality, in patients with type 2 diabetes and recent acute coronary syndrome.Keywords: GLP-1, incretin, pharmacology, GetGoal, T2DMPetersen ABChristensen MDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2013, Iss default, Pp 217-231 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Petersen AB Christensen M Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
description	Andreas B Petersen,1 Mikkel Christensen1,21Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark; 2Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, Copenhagen, DenmarkAbstract: The glucagon-like peptide (GLP)-1 receptor agonist lixisenatide (Lyxumia®) was approved for marketing by the European Medicines Agency in February 2013 and has been evaluated in a clinical study program called GetGoal. Lixisenatide activates the GLP-1 receptor and thereby exercises the range of physiological effects generated by GLP-1, which consist of increased insulin secretion, inhibition of glucagon secretion, and decreased gastrointestinal motility alongside the promotion of satiety. In the GetGoal study program, lixisenatide demonstrated significant reductions in glycated hemoglobin (HbA1c), and fasting and postprandial plasma glucose compared with placebo. The effect on glycemia was evident, with both monotherapy and in combination with insulin and various oral antidiabetic agents. Furthermore, a general trend towards reduced bodyweight was reported. In head-to-head trials with the other GLP-1 receptor agonists (exenatide and liraglutide) on the market, lixisenatide demonstrated a superior effect with respect to reduction in postprandial plasma glucose and had a tendency towards fewer adverse events. However, lixisenatide seemed to be less efficient or at best, equivalent to exenatide and liraglutide in reducing HbA1c, fasting plasma glucose, and bodyweight. The combination of a substantial effect on postprandial plasma glucose and a labeling with once daily administration separates lixisenatide from the other GLP-1 receptor agonists. The combination of basal insulin, having a lowering effect on fasting plasma glucose, and lixisenatide, curtailing the postprandial glucose excursions, makes sense from a clinical point of view. Not surprisingly, lixisenatide is undergoing clinical development as a combination product with insulin glargine (Lantus®). At present the main place in therapy of lixisenatide seems to be in combination with basal insulin. A large multicenter study will determine the future potential of lixisenatide in preventing cardiovascular events and mortality, in patients with type 2 diabetes and recent acute coronary syndrome.Keywords: GLP-1, incretin, pharmacology, GetGoal, T2DM
format	article
author	Petersen AB Christensen M
author_facet	Petersen AB Christensen M
author_sort	Petersen AB
title	Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
title_short	Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
title_full	Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
title_fullStr	Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
title_full_unstemmed	Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
title_sort	clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/7b095839cdb5437283aae518cecf7f0c
work_keys_str_mv	AT petersenab clinicalpotentialoflixisenatideoncedailytreatmentfortype2diabetesmellitus AT christensenm clinicalpotentialoflixisenatideoncedailytreatmentfortype2diabetesmellitus
_version_	1718402903394222080

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus

Ejemplares similares